PRO051

Investigators presented intriguing data from a trial of an experimental exon skipping drug for Duchenne muscular dystrophy, at the 2010 American Academy of Neurology meeting

posted on April 14, 2010 - 3:21am
The multinational pharmaceutical company GlaxoSmithKline (GSK) and the Dutch biotechnology company Prosensa  announced "intriguing results" following a 12-person trial of an experimental "exon skipping" therapeutic for Duchenne muscular dystrophy (DMD).
posted on December 31, 2009 - 1:17am
QUEST Vol. 17, No. 1
Featured in this issue: Duchenne and Becker MD ** Facioscapulohumeral MD ** Friedreich's ataxia ** Limb-Girdle muscular dystrophy ** Myotonic dystrophy ** Spinal muscular atrophy

A multinational pharmaceutical company has committed to developing Prosensa's exon skipping compound for DMD

posted on October 19, 2009 - 9:00pm
On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD). The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

A multinational pharmaceutical company has committed to developing Prosensa's exon-skipping compound for DMD

posted on October 13, 2009 - 12:50pm
On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon-skipping” compound PRO051 for Duchenne muscular dystrophy (DMD). The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.
posted on April 1, 2009 - 4:12pm
QUEST Vol. 16, No. 2
This article contains items about: Duchenne muscular dystrophy and spinal muscular atrophy